Bayer and the Broad Institute of MIT and Harvard expand partnership to advance drug discovery research for novel cancer treatments. Bayer and the Broad Institute of MIT and Harvard announced today that they have extended their multi-disciplinary research partnership by an additional five years, to develop and advance novel cancer treatments. The expanded agreement will focus on a…
Bayer In Agreement To Develop Therapies Targeting Genetic Cancer Drivers
Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer. Bayer has entered into an exclusive global collaboration with Loxo Oncology, Inc., a biopharmaceutical company based in Stamford, Conn. for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195. Both compounds are being investigated in global studies for the treatment of…
Strong Start to the Year for Bayer
Bayer Reports Increased Sales, Boosted by Pharmaceuticals
Another record year for Bayer — good progress with the acquisition of Monsanto. Bayer reported “a very successful year” in 2016, both strategically and operationally. “We again posted a record operating performance — and are making good progress with the agreed acquisition of Monsanto as well,” Werner Baumann, management board chairman, said on Wednesday at a…